U.S. Pharma Industry Analysis
UpdatedJul 27, 2024
DataAggregated Company Financials
Companies283
- 7D-0.6%
- 3M8.2%
- 1Y17.9%
- YTD13.7%
The Pharma is pretty flat in the last 7 days, but Bristol-Myers Squibb has stood out, gaining 18%. The past year has been better, since the industry has gained 18% in that time. Looking forward, earnings are forecast to grow by 23% annually.
Industry Valuation and Performance
Has the U.S. Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 27 Jul 2024 | US$1.9t | US$356.5b | US$13.2b | 16.3x | 147.5x | 5.4x |
| Mon, 24 Jun 2024 | US$2.0t | US$358.2b | US$14.1b | 16.5x | 139x | 5.5x |
| Wed, 22 May 2024 | US$1.9t | US$358.3b | US$14.1b | 18.3x | 133.6x | 5.2x |
| Fri, 19 Apr 2024 | US$1.8t | US$357.7b | US$29.8b | 20.3x | 60.2x | 5x |
| Sun, 17 Mar 2024 | US$1.9t | US$355.4b | US$22.5b | 19.8x | 82.7x | 5.2x |
| Tue, 13 Feb 2024 | US$1.9t | US$354.7b | US$22.8b | 33.3x | 81.7x | 5.2x |
| Thu, 11 Jan 2024 | US$1.8t | US$375.2b | US$33.9b | 27.8x | 52.3x | 4.7x |
| Sat, 09 Dec 2023 | US$1.7t | US$375.1b | US$33.9b | 26.6x | 48.8x | 4.4x |
| Mon, 06 Nov 2023 | US$1.6t | US$376.9b | US$33.9b | 18.5x | 48.1x | 4.3x |
| Wed, 04 Oct 2023 | US$1.6t | US$381.8b | US$43.8b | 19x | 37.6x | 4.3x |
| Fri, 01 Sep 2023 | US$1.7t | US$381.4b | US$43.8b | 19.7x | 39.4x | 4.5x |
| Sun, 30 Jul 2023 | US$1.7t | US$393.6b | US$61.5b | 18.5x | 27.8x | 4.3x |
| Tue, 27 Jun 2023 | US$1.7t | US$392.8b | US$60.1b | 18.6x | 28.8x | 4.4x |
| Thu, 25 May 2023 | US$1.7t | US$392.9b | US$60.5b | 18.3x | 28.1x | 4.3x |
| Sat, 22 Apr 2023 | US$1.7t | US$402.6b | US$63.3b | 17.8x | 26.3x | 4.1x |
| Mon, 20 Mar 2023 | US$1.5t | US$401.1b | US$69.3b | 15.5x | 22.2x | 3.8x |
| Wed, 15 Feb 2023 | US$1.7t | US$401.8b | US$68.8b | 18x | 24.3x | 4.2x |
| Fri, 13 Jan 2023 | US$1.7t | US$403.7b | US$70.6b | 17.5x | 24.5x | 4.3x |
| Sun, 11 Dec 2022 | US$1.8t | US$403.7b | US$70.7b | 16.5x | 24.8x | 4.3x |
| Tue, 08 Nov 2022 | US$1.7t | US$403.8b | US$71.4b | 14.9x | 23.6x | 4.2x |
| Thu, 06 Oct 2022 | US$1.6t | US$403.0b | US$71.3b | 13x | 22.3x | 3.9x |
| Sat, 03 Sep 2022 | US$1.6t | US$403.0b | US$71.3b | 14.6x | 21.8x | 3.9x |
| Mon, 01 Aug 2022 | US$1.7t | US$405.2b | US$69.8b | 21.5x | 23.9x | 4.1x |
| Wed, 29 Jun 2022 | US$1.7t | US$392.6b | US$64.9b | 22.1x | 26.4x | 4.4x |
| Fri, 27 May 2022 | US$1.7t | US$392.5b | US$64.7b | 21x | 26.1x | 4.3x |
| Sun, 24 Apr 2022 | US$1.6t | US$374.9b | US$59.9b | 21.4x | 27.2x | 4.3x |
| Tue, 22 Mar 2022 | US$1.6t | US$373.7b | US$60.3b | 20.6x | 27.3x | 4.4x |
| Thu, 17 Feb 2022 | US$1.6t | US$377.3b | US$55.3b | 21.5x | 28.1x | 4.1x |
| Sat, 15 Jan 2022 | US$1.6t | US$361.3b | US$37.8b | 24.3x | 42.3x | 4.4x |
| Mon, 13 Dec 2021 | US$1.5t | US$361.1b | US$38.1b | 21.7x | 40.6x | 4.3x |
| Wed, 10 Nov 2021 | US$1.6t | US$358.7b | US$38.6b | 24.3x | 41.2x | 4.4x |
| Fri, 08 Oct 2021 | US$1.5t | US$337.7b | US$24.8b | 19.4x | 60.6x | 4.5x |
| Sun, 05 Sep 2021 | US$1.6t | US$338.5b | US$25.8b | 20.6x | 61.6x | 4.7x |
| Tue, 03 Aug 2021 | US$1.6t | US$338.5b | US$25.8b | 20.7x | 61.4x | 4.7x |
Price to Earnings Ratio
61.4x
Current Industry PE
- Investors are optimistic on the American Pharmaceuticals industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 147x which is higher than its 3-year average PE of 46.5x.
- The 3-year average PS ratio of 4.5x is lower than the industry's current PS ratio of 5.4x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 20% per year over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.64% | |
| Healthcare | 1.23% | |
| Pharma | -0.60% | |
| Pharma | -0.60% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb | US$50.45 | 18.3% +US$15.8b | -17.8% | PS2.2x | |
| JNJ Johnson & Johnson | US$160.64 | 3.8% +US$14.4b | -7.9% | PE23.6x | |
| PFE Pfizer | US$30.77 | 2.7% +US$4.5b | -14.7% | PS3.2x | |
| ITCI Intra-Cellular Therapies | US$80.39 | 7.4% +US$583.8m | 32.2% | PS16.5x | |
| ZTS Zoetis | US$179.84 | 0.7% +US$574.9m | -5.3% | PE34.3x |
